Ferring Pharmaceuticals acquires global rights to MILPROSA (progesterone vaginal ring)
Saint-Prex, Switzerland – September 28, 2015 –
Ferring Pharmaceuticals announced today that it has acquired the global rights to MILPROSATM (progesterone vaginal ring) from Teva Women’s Health, Inc. MILPROSA has the potential to be the first once-weekly progesterone treatment for luteal phase support in women undergoing Assisted Reproductive Technology (ART) treatment if approved by regulatory authorities in the United States.
MILPROSA is a soft, flexible silicone-based vaginal ring designed to deliver a daily 11 mg dose of progesterone over the course of one week.1
“Ferring is a leader in infertility and MILPROSA, if approved, would enhance our broad treatment portfolio in this area. Equally important to Ferring is that MILPROSA would offer a weekly treatment regimen for patients and a new treatment option for doctors,” said Michel Pettigrew, President of the Ferring Executive Board and COO.
– ENDS –
About Ferring Pharmaceuticals
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.
MILPROSA and FERRING are trademarks of Ferring B.V.
For more information, please contact
Nicole Barraud-Estoppey
+41 (0) 58 301 00 53
Nicole.Barraud-Estoppey@ferring.com
Helen Gallagher
+41 (0) 58 301 00 51
helen.gallagher@ferring.com
References
- Stadtmauer, L. et al. Fertil Steril 2013;99:1543–9
